Solara Active Pharma Reports Zero Deviation in Rights Issue Proceeds Utilization
Solara Active Pharma Sciences Ltd 路 Others (Uncategorized) 路 17 Oct 2026, 12:59 am
Solara Active Pharma Reports Zero Deviation in Rights Issue Proceeds Utilization CRISIL Ratings issued the Monitoring Agency Report for Solara Active Pharma Sciences for the quarter ended 30th Sep'26, confirming zero deviation in rights issue proceeds utilization. Out of the revised net proceeds of Rs 446.95 crore, the company has deployed Rs 439.88 crore, including Rs 334.71 crore fully utilized toward debt repayment and Rs 105.17 crore toward general corporate purposes. Unutilized funds stand at Rs 7.07 crore, comprising Rs 3.33 crore yet to be received from calls and Rs 3.74 crore held across monitoring and escrow accounts.
Original exchange filing (PDF)
More announcements from Solara Active Pharma Sciences Ltd
- Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended September 30, 2026 路 23 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding the dispatch of Final Reminder -cum-Forfeiture Notice for the payment of outstanding call money to the holders .... 路 18 Oct 2026
- Audio recordings of Q2 FY27 earnings call conducted on October 16, 2026, for the quarter ended September 30, 2026 路 17 Oct 2026
- Solara Active Pharma Sciences Limited has informed the exchange about the Statement of Deviation/Variation in utilization of funds raised though Rights issue for the quarter ended September 30 2026 路 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding grant of 470000 options under Solara Employee Stock Option Plan 2024 路 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding a Press Release dated October 16, 2026, titled "Solara''s Q2 FY 27 revenue grows 33% to INR 4,178 Mn and EBITDA .... 路 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 8,300 Equity shares pursuant to exercise of ESOP options. 路 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter .... 路 16 Oct 2026
